Biomerica Reports AG真人官方-World Data Showing 49% Reduction in IBS Symptoms with inFoods庐 IBS using a First of Its Kind AG真人官方-Time IBS Patient Feedback System
Biomerica (NASDAQ: BMRA) reported significant real-world data for its inFoods庐 IBS diagnostic-guided therapy, showing remarkable symptom reduction in IBS patients. Data from over 360 patients demonstrated a 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period.
The company also launched a HIPAA-compliant real-time patient feedback system that enables physicians to track symptoms and adjust treatment plans accordingly. These results complement a peer-reviewed study published in Gastroenterology, which showed that patients on an inFoods庐 IBS-guided diet experienced significantly more abdominal pain relief compared to placebo (59.6% vs. 42.1%, p-value=0.02).
The solution targets a substantial market, as IBS affects 10-15% of U.S. adults, offering a personalized, non-drug approach to identify and eliminate specific food triggers causing IBS symptoms.
Biomerica (NASDAQ: BMRA) ha presentato dati reali significativi per la sua terapia guidata dalla diagnosi inFoods庐 IBS, mostrando una notevole riduzione dei sintomi nei pazienti con IBS. I dati raccolti da oltre 360 pazienti hanno evidenziato una riduzione del 48,5% del dolore gastrointestinale e una riduzione del 49,8% del gonfiore nell'arco di 8 settimane.
L'azienda ha inoltre lanciato un sistema di feedback in tempo reale conforme a HIPAA, che consente ai medici di monitorare i sintomi e modificare i piani di trattamento di conseguenza. Questi risultati integrano uno studio peer-reviewed pubblicato su Gastroenterology, che ha dimostrato come i pazienti seguendo una dieta guidata da inFoods庐 IBS abbiano sperimentato un sollievo dal dolore addominale significativamente maggiore rispetto al placebo (59,6% vs. 42,1%, valore p=0,02).
La soluzione si rivolge a un mercato rilevante, dato che l'IBS colpisce il 10-15% degli adulti negli Stati Uniti, offrendo un approccio personalizzato e non farmacologico per identificare ed eliminare specifici alimenti scatenanti i sintomi dell'IBS.
Biomerica (NASDAQ: BMRA) present贸 datos significativos del mundo real para su terapia guiada por diagn贸stico inFoods庐 IBS, mostrando una notable reducci贸n de los s铆ntomas en pacientes con SII. Los datos de m谩s de 360 pacientes demostraron una reducci贸n del 48.5% en el dolor gastrointestinal y una reducci贸n del 49.8% en la hinchaz贸n durante un per铆odo de 8 semanas.
La compa帽铆a tambi茅n lanz贸 un sistema de retroalimentaci贸n en tiempo real compatible con HIPAA que permite a los m茅dicos monitorear los s铆ntomas y ajustar los planes de tratamiento en consecuencia. Estos resultados complementan un estudio revisado por pares publicado en Gastroenterology, que mostr贸 que los pacientes con una dieta guiada por inFoods庐 IBS experimentaron un alivio significativamente mayor del dolor abdominal en comparaci贸n con el placebo (59.6% vs. 42.1%, valor p=0.02).
La soluci贸n apunta a un mercado considerable, ya que el SII afecta al 10-15% de los adultos en EE. UU., ofreciendo un enfoque personalizado y no farmacol贸gico para identificar y eliminar los desencadenantes alimentarios espec铆ficos que causan los s铆ntomas del SII.
Biomerica (NASDAQ: BMRA)電� inFoods庐 IBS 歆勲嫧 旮半皹 旃橂鞐� 雽�頃� 鞁れ牅 雿办澊韯办棎靹� 瓿茧靹� 雽�鞛� 歃濏泟甑�(IBS) 頇橃瀽鞚� 歃濎儊 臧愳唽臧� 雸堨棎 霛勱矊 雮橅儉雮嫟瓿� 氤搓碃頄堨姷雼堧嫟. 360氇� 鞚挫儊鞚� 頇橃瀽 雿办澊韯半ゼ 韱淀暣 8欤� 霃欖晥 鞙勳灔 韱奠鞚� 48.5% 臧愳唽顷橁碃 氤惦秬 韺诫臧愳澊 49.8% 臧愳唽頃� 瓴冹溂搿� 雮橅儉雮姷雼堧嫟.
須岇偓電� 霕愴暅 HIPAA 欷�靾� 鞁れ嫓臧� 頇橃瀽 頂茧摐氚� 鞁滌姢韰滌潉 霃勳瀰頃橃棳 鞚橃偓霌れ澊 歃濎儊鞚� 於旍爜顷橁碃 旃橂 瓿勴殟鞚� 臁办爼頃� 靾� 鞛堧弰搿� 頄堨姷雼堧嫟. 鞚� 瓴瓣臣電� Gastroenterology鞐� 瓴岇灛霅� 霃欕 瓴�韱� 鞐瓣惮鞕�霃� 鞚检箻頃橂┌, inFoods庐 IBS 鞁濍嫧鞚� 霐半ジ 頇橃瀽霌れ澊 鞙勳暯甑办棎 牍勴暣 氤淀喌 鞕勴檾臧� 鞙犾潣頃橁矊 雿� 旎胳潓鞚� 氤挫棳欷嶋媹雼�(59.6% 雽� 42.1%, p臧�=0.02).
鞚� 靻旊（靺橃潃 氙戈淡 靹膘澑鞚� 10-15%臧� 鞓來枼鞚� 氚涬姅 IBS霛茧姅 韥� 鞁滌灔鞚� 雽�靸侅溂搿� 頃橂┌, 韸轨爼 鞚岇嫕 鞙犽皽 鞖旍澑鞚� 鞁濍硠顷橁碃 鞝滉卑頃橂姅 臧滌澑 毵烄钉順� 牍勳暯氍� 鞝戧芳氩曥潉 鞝滉车頃╇媹雼�.
Biomerica (NASDAQ : BMRA) a pr茅sent茅 des donn茅es significatives issues du monde r茅el pour sa th茅rapie guid茅e par diagnostic inFoods庐 IBS, montrant une r茅duction remarquable des sympt么mes chez les patients atteints du SCI. Les donn茅es recueillies aupr猫s de plus de 360 patients ont montr茅 une r茅duction de 48,5 % de la douleur gastro-intestinale et une r茅duction de 49,8 % des ballonnements sur une p茅riode de 8 semaines.
L'entreprise a 茅galement lanc茅 un syst猫me de retour d'information en temps r茅el conforme 脿 la HIPAA, permettant aux m茅decins de suivre les sympt么mes et d'ajuster les plans de traitement en cons茅quence. Ces r茅sultats compl猫tent une 茅tude 茅valu茅e par des pairs publi茅e dans Gastroenterology, qui a montr茅 que les patients suivant un r茅gime guid茅 par inFoods庐 IBS ont ressenti un soulagement significativement plus important de la douleur abdominale par rapport au placebo (59,6 % contre 42,1 %, valeur p=0,02).
Cette solution cible un march茅 important, puisque le SCI touche 10 脿 15 % des adultes aux 脡tats-Unis, offrant une approche personnalis茅e et non m茅dicamenteuse pour identifier et 茅liminer les d茅clencheurs alimentaires sp茅cifiques responsables des sympt么mes du SCI.
Biomerica (NASDAQ: BMRA) berichtete 眉ber bedeutende AG真人官方-World-Daten zu seiner diagnostisch gef眉hrten Therapie inFoods庐 IBS, die eine bemerkenswerte Symptomreduktion bei IBS-Patienten zeigte. Daten von 眉ber 360 Patienten zeigten eine 48,5%ige Reduktion der gastrointestinalen Schmerzen und eine 49,8%ige Reduktion von Bl盲hungen 眉ber einen Zeitraum von 8 Wochen.
Das Unternehmen hat au脽erdem ein HIPAA-konformes Echtzeit-Patientenfeedback-System eingef眉hrt, das 脛rzten erm枚glicht, Symptome zu verfolgen und Behandlungspl盲ne entsprechend anzupassen. Diese Ergebnisse erg盲nzen eine von Experten begutachtete Studie, die in Gastroenterology ver枚ffentlicht wurde und zeigte, dass Patienten mit einer inFoods庐 IBS-gef眉hrten Di盲t signifikant mehr Linderung von Bauchschmerzen erfuhren als die Placebogruppe (59,6% vs. 42,1%, p-Wert=0,02).
Die L枚sung richtet sich an einen bedeutenden Markt, da IBS 10-15% der Erwachsenen in den USA betrifft, und bietet einen personalisierten, medikamentenfreien Ansatz zur Identifikation und Eliminierung spezifischer Nahrungsmittel-Ausl枚ser f眉r IBS-Symptome.
- AG真人官方-world data shows 48.5% reduction in GI pain and 49.8% reduction in bloating
- Launch of new HIPAA-compliant real-time feedback system for better treatment monitoring
- Peer-reviewed study validates efficacy with 59.6% pain relief vs 42.1% for placebo
- Large addressable market with 10-15% of U.S. adults affected by IBS
- Non-pharmaceutical solution reducing dependency on medications with side effects
- None.
Insights
Biomerica's inFoods IBS test shows impressive 49% symptom reduction in real-world data, validating its effectiveness as a non-drug IBS solution.
Biomerica's latest real-world data for their inFoods庐 IBS test represents a significant advancement in IBS management. The reported
What makes this approach particularly valuable is its diagnostic-guided methodology. Rather than treating IBS with a one-size-fits-all approach, inFoods庐 identifies patient-specific food triggers that exacerbate symptoms. This personalized elimination strategy addresses a fundamental gap in IBS care, where trigger identification has traditionally been a process of lengthy trial and error.
The new HIPAA-compliant real-time feedback system represents an important clinical advancement. This platform enables ongoing monitoring of patient responses, allowing for dynamic treatment adjustments based on individual progress. For gastroenterologists, this transforms IBS management from a static to an adaptive process, potentially improving long-term outcomes.
The peer-reviewed validation published in Gastroenterology (showing
The data suggests inFoods庐 IBS could become a first-line approach for IBS patients, potentially reducing healthcare costs associated with repeated office visits, medication trials, and symptom management.
Biomerica's inFoods庐 IBS test represents a paradigm shift in functional gastroenterology diagnostics. The company has effectively transformed a diagnostic test into a complete therapeutic ecosystem through their new real-time feedback platform. This closed-loop system鈥攖est, intervene, monitor, adjust鈥攑laces Biomerica ahead of competitors who typically offer only point-in-time diagnostics without the ongoing management component.
The real-world evidence (RWE) from 360+ patients carries substantial weight with payers and providers. The
From a healthcare economics perspective, the inFoods庐 approach potentially reduces downstream costs from repeated specialist visits, pharmaceutical trials, and symptom management. The diagnostic-guided therapy model exemplifies precision medicine principles鈥攊dentifying specific triggers rather than generalized treatment鈥攚hich typically commands premium reimbursement rates.
The HIPAA-compliant feedback system creates a proprietary data asset that strengthens Biomerica's competitive moat. As this database grows, the accumulated insights could further refine their algorithm and potentially expand applications beyond IBS. This data-driven approach transforms what could be a single-use diagnostic into an ongoing patient management platform with recurring revenue potential.
With IBS affecting
- AG真人官方-World Impact: Initial data from over 360 patients shows inFoods庐 IBS delivered an average
48.5% reduction in gastrointestinal pain and a49.8% reduction in bloating over an 8-week period - First-of-Its-Kind inFoods庐 IBS Feedback Platform: New real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomes
- Precision Medicine: inFoods庐 IBS identifies specific individual food triggers that can cause IBS symptoms (bloating, pain, diarrhea, and constipation) offering a personalized, non-drug solution
IRVINE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), an innovator in diagnostic-guided therapy, today announced compelling real-world results demonstrating the effectiveness of its inFoods庐 IBS product, along with the launch of a proprietary real-time patient feedback system to enhance symptom tracking and improve patient outcomes.
The initial analysis from more than 360 patients who enrolled in the real world inFoods庐 IBS study revealed an average:
48.5% reduction in gastrointestinal (GI) pain49.8% reduction in bloating
This ongoing study tracks symptom reduction from a two-week baseline through an eight-week intervention, during which patients eliminate specific trigger foods identified using the InFoods庐 IBS diagnostic system. These real-world outcomes align with鈥攁nd in some cases exceed鈥攔esults from prior randomized clinical trials conducted at leading U.S. medical centers.
"We鈥檙e proud to share this real-world data that confirms the significant benefit inFoods庐 IBS delivers to patients suffering from IBS," said Zack Irani, CEO of Biomerica. "Our real-time symptom tracking platform gives physicians clinical insight throughout treatment, creating a personalized and dynamic approach to care."
New AG真人官方-Time Feedback System Enhances Clinical Decision-Making
Biomerica鈥檚 HIPAA-compliant platform provides physicians with visibility into patient-reported outcomes鈥攕uch as abdominal discomfort, bloating, and overall well-being鈥攖hroughout the course of inFoods庐 therapy. This allows clinicians to make data-informed decisions and adjust treatment plans with greater speed and accuracy, ultimately leading to improved patient outcomes.
Peer-Reviewed Results Published in Gastroenterology
The real-world findings build on results from a peer-reviewed study published in Gastroenterology and led by Cleveland Clinic and the University of Michigan. That study demonstrated that patients on an InFoods庐 IBS -guided diet experienced significantly more abdominal pain relief compared to those on a placebo diet (
Addressing a Major Market Need
IBS affects an estimated
Biomerica鈥檚 inFoods庐 IBS diagnostic-guided therapy offers an innovative, affordable, and personalized solution to address these challenges, improving IBS management for both patients and healthcare providers.
For more information visit: www.inFoodsibs.com
About Biomerica (NASDAQ: )
Biomerica, Inc. () is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
About inFoods庐
The inFoods IBS test is designed to assess a patient鈥檚 above normal immunoreactivity to specific foods utilizing a simple finger-stick blood sample. Instead of difficult to manage broad dietary restrictions, physicians can now use the inFoods IBS information to make targeted, patient-specific recommendations about trigger foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The inFoods IBS test and clinical outcomes were studied at several prominent centers including Mayo Clinic, Beth Israel Deaconess Medical Center Inc. - a Harvard Medical School Teaching Hospital, Houston Methodist Hospital, and the University of Michigan. The clinical results for improvement in the Abdominal Pain Intensity (API) responder endpoint of >
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company鈥檚 current and future sales, revenues, overhead, expenses, cost of goods, operations and earnings, efficacy of the Company鈥檚 products and tests, FDA and/or international regulatory authorization for the Company鈥檚 products to be marketed and sold, including the inFoods IBS product, and the Company鈥檚 other current and future products, the possible expansion in to other markets, uniqueness of the Company鈥檚 products, accuracy of the Company鈥檚 tests and products, expected completion of clinical studies, new feedback system, pricing of the Company鈥檚 test kits, domestic and/or international market adoption and acceptance and demand for the Company鈥檚 products, future use of the Company's products by physicians to treat their patients, potential revenues from the sale of current or future products. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results, in the future, including, without limitation: earnings and other financial results; results of studies testing the efficacy of the Company鈥檚 inFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company鈥檚 products; availability of the Company鈥檚 test kits and other products; capacity, shipping logistics, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulatory compliance and oversite, and the Company鈥檚 ability to obtain patent protection on any aspects of its diagnostic or therapeutic technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact:
Zack Irani
949-645-2111
[email protected]
Source: Biomerica, Inc.
FAQ
What are the clinical results of Biomerica's inFoods IBS treatment (BMRA)?
How does Biomerica's inFoods IBS diagnostic system work?
What is the market potential for Biomerica's (BMRA) inFoods IBS product?
What new technology has Biomerica (BMRA) launched for IBS treatment monitoring?
How does inFoods IBS differ from traditional IBS treatments?
